Tibofem is a prescription medication that contains tibolone as its active component. Tibolone belongs to the women’s-health-focused class of synthetic steroid hormones used primarily for the management of menopausal symptoms. In Hong Kong, Tibofem is supplied as a 2.5 mg pill and is regulated as a prescription-only product by the Department of Health.
Tibolone is a synthetic steroid that exhibits selective tissue activity. After oral absorption, tibolone is metabolized into three major metabolites that each display distinct hormonal actions:
These combined effects provide a balanced hormonal milieu that mimics the natural decline of estrogen during menopause without fully replacing all endogenous hormones. The onset of symptom relief typically occurs within a few weeks, with peak effects observed after several months of continuous use.
Tibofem is approved in Hong Kong for the following indication:
The medication is intended for post-menopausal women who require hormone-based symptom control and who have no contraindications listed below. Tibofem is not indicated for use in pre-menopausal women, men, or for hormone replacement in surgical menopause unless specifically prescribed by a qualified clinician.
No robust, peer-reviewed evidence supports off-label uses of tibolone in Hong Kong. While some studies have examined tibolone for osteoporosis prevention, bone health benefits remain an investigational area and are not approved by local regulatory agencies. Clinicians may consider off-label use only after a thorough risk-benefit assessment and with explicit patient consent.
If any of the above conditions apply, discuss alternative therapies with a healthcare professional.
These effects are typically mild and transient. If they persist or worsen, seek medical advice.
Black-box warnings for tibolone emphasize the increased risk of thromboembolic events and stroke, particularly in older women or those with cardiovascular risk factors.
Because interaction data for many supplements are limited, patients should disclose all medications, herbal products, and over-the-counter remedies to their prescriber.
Dosage adjustments are rarely needed but may be considered in patients with significant hepatic impairment or those experiencing intolerable side effects. All dosing decisions must be individualized by a qualified healthcare provider.
Regular follow-up visits enable clinicians to balance symptom control with safety, especially in women over 60 years of age.
This article provides educational information about Tibofem and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Tibofem contains tibolone, a synthetic steroid that provides combined estrogenic, progestogenic, and androgenic activity through its metabolites. Traditional HRT typically involves separate estrogen and progesterone preparations, whereas tibolone delivers a single-molecule profile that may reduce the need for multiple pills.
While tibolone has shown modest bone-preserving effects in some studies, it is not approved in Hong Kong for osteoporosis prevention. Clinicians may consider other evidence-based options such as bisphosphonates or calcium-vitamin D supplementation.
Long-term safety data suggest that tibolone can be used for several years, but ongoing evaluation of cardiovascular and thrombotic risk is essential. Women over 60 years should have more frequent monitoring, and any new risk factors may prompt discontinuation.
Clinical trials have indicated a neutral to slightly increased risk of breast cancer with tibolone use in women with an intact uterus, particularly after prolonged therapy. Women with a personal or family history of breast cancer should discuss alternative treatments with their doctor.
Tibolone may modestly increase HDL (“good”) cholesterol while slightly lowering LDL (“bad”) cholesterol. Routine lipid monitoring is advisable, especially in patients with existing dyslipidemia.
Concomitant use of tibolone with estrogen-containing contraceptives can increase estrogen exposure and potentially raise clotting risk. It is generally recommended to avoid overlapping hormone therapies unless specifically advised by a healthcare professional.
Baseline liver function tests are recommended before starting therapy, with follow-up testing at three months and then annually. Additional labs may be ordered based on individual risk factors.
Women who experience migraine with aura have an elevated risk of stroke when using estrogen-containing products. Tibolone’s mixed hormonal profile may still carry some risk, so a thorough risk assessment is needed before prescribing.
Take the missed tablet as soon as you remember, unless it is close to the time of your next scheduled dose. In that case, skip the missed tablet and continue with your regular dosing schedule. Do not double-dose.
Yes. Maintain a consistent 24-hour dosing interval regardless of time zone changes. If crossing the International Date Line, adjust the schedule forward or backward by one dose to stay on a 24-hour cycle.
